Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
9.3 NOK | +3.33% | +1.09% | +91.36% |
30/05 | Transcript : Lytix Biopharma AS, Q1 2024 Earnings Call, May 30, 2024 | |
30/05 | Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+91.36% | 42.18M | - | ||
+34.14% | 51.12B | B- | ||
-6.54% | 39.4B | B | ||
+35.45% | 38.48B | A | ||
+12.62% | 26.36B | B- | ||
-12.11% | 26.22B | C | ||
-13.43% | 20.96B | B | ||
+43.73% | 14.02B | B+ | ||
+31.81% | 12.49B | C+ | ||
-4.54% | 11.61B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LYTIX Stock
- Ratings Lytix Biopharma